Stayble Therapeutics AB (STABL)
XSTO XSTO Primary Summary
Stayble Therapeutics AB (STABL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Stayble Therapeutics AB ever had a stock split?
Stayble Therapeutics AB Profile
| Biotechnology Industry | Healthcare Sector | Mr. Andreas Gerward M.Sc. CEO | XSTO Exchange | SE0013513652 ISIN |
| Taiwan Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Stayble Therapeutics AB (publ) is a pioneering biotech company based in Gothenburg, Sweden, focusing on developing innovative treatments for chronic pain due to disc degeneration. Since its inception in 2015, the company has been at the forefront of addressing chronic low back and leg pain through cutting-edge medical solutions. Leveraging advanced research and development capabilities, Stayble Therapeutics AB (publ) aims to improve the quality of life for patients suffering from debilitating chronic pain conditions by introducing non-surgical, injectable treatments.
Products and Services
STA363
Stayble Therapeutics AB (publ) is dedicated to the development of STA363, a revolutionary injectable treatment designed specifically for chronic pain caused by disc degeneration. STA363 targets the core of the issue by being directly injected into the affected disc, providing a potentially long-lasting solution to individuals experiencing chronic low back and leg pain. This approach not only aims to alleviate pain but also to contribute to the field of pain management by offering an innovative, non-surgical alternative for patients.
